U.S. Senators Tim Scott and Cory Booker have introduced a bill to reauthorize the Sickle Cell Disease Treatment Demonstration Program, which was last renewed in 2018. The program aims to improve access to research and treatment for sickle cell disease (SCD), a genetic blood disorder primarily affecting African Americans, Latinos, and other minority groups.
According to the Centers for Disease Control and Prevention, approximately 100,000 individuals in the United States are affected by sickle cell disease. Those with SCD typically face a lower life expectancy compared to the general population.
Senator Scott emphasized the importance of reauthorizing this program: “Reauthorizing this program will allow us to expand access to research and treatment for rare blood diseases and reduce the number of people in already overwhelmed emergency rooms. I am glad to play a small role in easing the burden that SCD has on too many individuals and their families.” He added that the legislation would support continued innovation in SCD care.
Senator Booker also highlighted past successes of the program: “Since 2018, the Sickle Cell Disease Treatment Demonstration Program has expanded access to care for people suffering from SCD and saved lives,” he said. He urged Congress to reauthorize it so that advancements can continue for patients nationwide.
The full text of the proposed legislation is available online.
